Medtronic (NYSE:MDT) today announced a new real-world retrospective analysis highlighting positive outcomes with its MiniMed ...

A new real-world retrospective analysis published in Diabetes Care showed that users of the MiniMed™ 780G system achieved American Diabetes Association (ADA) recommended goals for time-in-range (TIR)— ...

New data presented at ATTD demonstrates the system's ability to help individuals with type 1 diabetes exceed international targets on outcome measures New data sought to evaluate the MiniMed™ 780G ...

With its advanced algorithm that provides autocorrections every 5 minutes, the latest data demonstrated that the MiniMed™ 780G system decreased rates of early morning hyperglycemia, known as dawn ...

For the first time, real-world data on the Medtronic Extended Infusion™ Set was presented (n=108) and the analysis showed an average infusion set wear time of 6.74 days. Almost half (48.2%) of the ...

GALWAY, Ireland, Sept. 2, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced two U.S. Food and Drug Administration (FDA) regulatory milestones ...

DUBLIN, June 11, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced CE (Conformité Européenne) Marking of its MiniMed™ 780G system, a next ...

Latest approval expands Medtronic CGM portfolio in the U.S. GALWAY, Ireland, April 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the U.S ...

Medtronic plc MDT presented new clinical and real-world data on the MiniMed 780G system at the 83rd American Diabetes Association Scientific Sessions. In April, the FDA approved Medtronic's MiniMed ...